Aug 13, 2026, 22:04 UTC
Alpha Cognition reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer's treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter.
Jul 29, 2026, 12:30 UTC
Alpha Cognition Inc. received a European patent from the European Patent Office covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for treating mild-to-moderate Alzheimer's disease.
Source:Jul 9, 2026, 02:15 UTC
Cognition launches SWE-1.7, a new AI model trained from Kimi K2.7, available at 1,000 tokens per second.
Source:Jun 23, 2026, 13:00 UTC
Alpha Cognition Inc. elected Dr. Robert Wills as Chairman of the Board.
Source: